Filing Analysis
Cardlytics, Inc. filed an 8-K to announce the release of its financial results for the three and six months ended June 30, 2026. The filing serves as a formal notice that earnings data has been made public via press release.
📋 Key Facts
- Reported date: August 5, 2026
- Financial period covered: Three and six months ended June 30, 2026
- The company issued a press release (Exhibit 99.1) containing the results.
- A conference call was scheduled to discuss financial results and recent corporate highlights.
Cardlytics received a Nasdaq delisting notice due to the stock price remaining below $1.00 for 30 consecutive business days. To regain compliance, the company is implementing a 1-for-10 reverse stock split effective June 5, 2026.
🚩 Red Flags
- Delisting notice from Nasdaq
- Reverse stock split (typically a sign of extreme share price distress)
- Multiple 8-K items (3.01 and 3.03) in a single filing
- Significant reduction in authorized share capital
📋 Key Facts
- Received Nasdaq delisting notice on June 3, 2026, for violation of Rule 5550(a)(2) (minimum bid price of $1.00).
- Implementing a 1-for-10 reverse stock split effective June 5, 2026, at 5:00 p.m. ET.
- Authorized shares reduced from 100,000,000 to 10,000,000.
- Shares outstanding will decrease from 58,078,634 to approximately 5,807,863.
- Split-adjusted trading on Nasdaq begins June 8, 2026.
- New CUSIP number: 14161W303.
Cardlytics, Inc. (CDLX) held its Annual Meeting on May 20, 2026, at which stockholders approved four proposals. Most critically, stockholders approved a reverse stock split authorization giving the Board discretion to execute a 1-for-5 to 1-for-15 reverse split of common stock at any time prior to the 2027 Annual Meeting. This strongly signals potential Nasdaq compliance concerns given the wide split ratio range authorized.
🚩 Red Flags
- Reverse stock split authorization with a very wide ratio range (1-for-5 to 1-for-15) suggests significant stock price distress and likely Nasdaq minimum bid price non-compliance ($1.00 minimum)
- Upper end of split ratio (1-for-15) implies current stock price could be as low as $0.07-$0.20/share range to bring it back to a compliant level, indicating severe price deterioration
- Board granted sole discretion to act at any time through 2027 Annual Meeting, creating prolonged uncertainty for shareholders
- Say-on-pay vote was relatively weak: 9,840,538 For vs. 3,379,898 Against (~74.4% approval), suggesting shareholder dissatisfaction with executive compensation
- Significant withhold votes against Jack Klinck (2,008,136) and Shrishti Gupta (2,016,667), nearly 15% of non-broker votes — possible governance concerns
- Deloitte & Touche retention as auditor amid what appears to be a distressed stock situation warrants monitoring
📋 Key Facts
- Annual Meeting held May 20, 2026; 34,996,216 of 55,070,709 shares (63.54%) represented
- Proposal 3 APPROVED: Reverse stock split authorized at Board's discretion, ratio ranging from 1-for-5 to 1-for-15, inclusive, effective any time prior to 2027 Annual Meeting
- Reverse split vote: 32,745,480 For vs. 2,205,871 Against (93.7% approval among voting shares)
- Corresponding proportionate reduction in total authorized shares approved alongside the reverse split
- Board retains sole discretion on timing, exact ratio selection (1-for-5 through 1-for-15), or full abandonment
- Proposal 1 APPROVED: Three Class II directors elected — Amit Gupta (12.7M for), Jack Klinck (11.3M for), Shrishti Gupta (11.3M for) — to serve until 2029
- Proposal 2 APPROVED: Deloitte & Touche LLP ratified as auditor for fiscal year ending December 31, 2026 (34,494,578 For vs. 404,398 Against)
- Proposal 4 APPROVED (advisory): Named executive officer compensation approved with 9,840,538 For vs. 3,379,898 Against — notably weak approval (~74.4% of non-broker votes)
- 21,725,998 broker non-votes on director election and say-on-pay proposals
- Filing signed by David Evans, Chief Financial Officer
Nick Lynton, the Chief Legal and Privacy Officer of Cardlytics, Inc., has resigned effective July 3, 2026, or upon the appointment of a successor. The company has entered into a Transition Agreement providing for a severance package and an advisory role during the transition period.
📋 Key Facts
- Nick Lynton notified the company of his resignation on May 10, 2026.
- The resignation is effective July 3, 2026, or earlier if a successor is appointed.
- Lynton will receive a lump sum separation payment of $380,000.
- The company will provide COBRA premium reimbursement for up to 12 months.
- An additional lump sum payment of $70,320.21 is scheduled for payment in Q1 2027.
- The Transition Agreement replaces a previous Separation Pay Agreement dated August 8, 2022.
Cardlytics, Inc. announced its financial results for the first quarter ended March 31, 2026, and scheduled a conference call to discuss performance.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were released on May 7, 2026.
- The announcement includes a press release (Exhibit 99.1).
- The filing is signed by CFO David Evans.
- The disclosure is made under Item 2.02 (Results of Operations and Financial Condition).
Cardlytics, Inc. completed the sale of its Bridg platform assets to PAR Technology Corporation on March 24, 2026. The consideration for the sale consisted of 1,810,222 shares of PAR common stock.
🚩 Red Flags
- Divestiture of a major technology platform (Bridg) may indicate a significant shift in business strategy or a need to simplify operations.
- The consideration is entirely in PAR common stock, exposing Cardlytics to the market volatility of a single external security.
📋 Key Facts
- Closing date of the Bridg Sale was March 24, 2026.
- The buyer is DB Sub, LLC, an indirect wholly owned subsidiary of PAR Technology Corporation.
- Cardlytics received 1,810,222 shares of PAR common stock as consideration.
- The assets sold include all properties and rights primarily related to the Bridg platform.
- The filing includes pro forma financial statements for the years ended December 31, 2023, 2024, and 2025 to reflect the impact of the disposition.
Cardlytics, Inc. reported its financial results for the fourth quarter and fiscal year ended December 31, 2025. The company furnished a press release and announced a conference call to discuss these results.
📋 Key Facts
- The filing was made on March 4, 2026, to report results for the period ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the financial details was furnished as Exhibit 99.1.
- The company scheduled a conference call to discuss corporate highlights and financial performance.
Cardlytics, Inc. has entered into a definitive agreement to sell its Bridg platform assets to PAR Technology Corporation (via DB Sub, LLC). The transaction is structured as an asset sale where the consideration will be primarily delivered in shares of PAR Common Stock.
🚩 Red Flags
- Significant divestiture of a core platform (Bridg) suggests a strategic pivot or urgent need for liquidity/restructuring.
- The consideration is primarily in the stock of another company (PAR), which introduces significant market volatility risk to the value received by Cardlytics shareholders.
- Asset sale structure: The buyer is only acquiring specific assets and rights, not the entire company, leaving the remaining corporate shell's future uncertain.
📋 Key Facts
- Signing Date: January 23, 2026.
- Buyer: PAR Technology Corporation and its subsidiary DB Sub, LLC.
- Assets Sold: All assets, properties, and rights related to the Bridg platform.
- Purchase Consideration: A number of shares of PAR Common Stock equal to $27.5M (subject to adjustments up to a maximum of $30M) divided by the 15-day VWAP of PAR stock prior to closing.
- Non-Compete: Cardlytics is subject to a 5-year non-competition and non-solicitation covenant regarding the Bridg assets.
- Closing Deadline: The agreement may be terminated if conditions are not met by March 24, 2026.
Cardlytics, Inc. announced the appointment of David Evans as Chief Financial Officer, effective January 12, 2026, replacing Alexis DeSieno. Ms. DeSieno will transition to a non-officer advisory role through March 6, 2026.
🚩 Red Flags
- Executive turnover in the CFO position can sometimes signal internal friction or transition challenges, though mitigated here by an advisory period.
- Clawback provision on signing bonus indicates a high priority for retention of this specific hire.
📋 Key Facts
- David Evans appointed CFO, Principal Financial Officer, and Principal Accounting Officer effective Jan 12, 2026.
- Alexis DeSieno departing officer role; will serve as non-officer advisor until March 6, 2026.
- Mr. Evans' compensation includes a $400,000 base salary and a target bonus of 100% of base salary.
- Grant of 1,000,000 Restricted Stock Units (RSUs) under the Inducement Plan with staggered vesting starting Feb 1, 2027.
- Signing bonus of $200,000 subject to a 12-month clawback if he leaves voluntarily.
- Mr. Evans is a former Cardlytics officer (CAO/CFO) from 2014–2020.
Cardlytics, Inc. announced that CFO Alexis DeSieno intends to resign, effective either upon the appointment of a successor or March 6, 2026. The departure is not due to any disagreements regarding company operations, policies, practices, financial statements, or internal controls.
🚩 Red Flags
- Planned departure of a key executive (CFO) creates potential transition risk and management instability in the short term.
📋 Key Facts
- CFO Alexis DeSieno notified the company of her intent to resign on December 3, 2025.
- Effective date: Earlier of successor appointment or March 6, 2026.
- The resignation is explicitly stated not to be due to any disagreements with the company's financial reporting or internal controls.
- Ms. DeSieno will transition into a non-officer advisory role if a successor is found before her departure date.
- She will continue to receive base salary and benefits through March 6, 2026.
Cardlytics, Inc. filed an 8-K to announce the release of its financial results for the three and nine months ended September 30, 2025.
📋 Key Facts
- Financial results announced for the three and nine months ended September 30, 2025.
- The company scheduled a conference call to discuss financial results and recent corporate highlights.
- Press release issued on November 5, 2025, is attached as Exhibit 99.1.
Cardlytics, Inc. has announced a workforce reduction plan involving approximately 90 full-time employees, representing about 24% of its total workforce. The company expects to incur roughly $2.3 million in non-recurring restructuring charges related to this initiative.
🚩 Red Flags
- Significant workforce reduction (24% of staff) suggests aggressive cost-cutting measures.
- Potential for additional unquantified impairment charges mentioned in the filing.
- Management uncertainty regarding the final total cost of restructuring.
📋 Key Facts
- Reduction of approximately 90 full-time employees (approx. 24% of current workforce).
- Estimated non-recurring charges of ~$2.3 million for severance and related costs.
- Most restructuring charges expected in Q4 ending December 31, 2025.
- Plan is part of a broader cost-reduction initiative to optimize cost structure.
Cardlytics, Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2025. The filing serves as a formal notice that a press release containing these results was issued on August 6, 2025.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2025.
- Announcement date: August 6, 2025.
- The filing includes a press release as Exhibit 99.1 regarding financial results and corporate highlights.
Cardlytics, Inc. entered into a Fourth Amendment to its Master Agreement with JPMorgan Chase Bank, extending the partnership term through November 18, 2028. The amendment includes adjustments to revenue-sharing components, specifically reducing the Supplier Billings Share starting January 1, 2026.
🚩 Red Flags
- Reduction in revenue-sharing percentage (Supplier Billings Share) starting in 2026 may impact future gross margins or top-line growth rates from this specific channel.
📋 Key Facts
- Entered into Fourth Amendment to Schedule #1 of the Master Agreement with JPMorgan Chase Bank on July 7, 2025.
- The term of the Master Agreement is extended until November 18, 2028.
- Effective January 1, 2026, the Supplier Billings Share (the portion of billings retained by Cardlytics) will be reduced.
- Despite the reduction, the Company notes that the retention rate remains higher than it was prior to the Third Amendment.
Cardlytics, Inc. has amended the offer letter and severance agreement for CEO Amit Gupta, including new equity grants (RSUs and PSUs) and enhanced severance terms.
🚩 Red Flags
- Increased executive compensation/equity dilution through the grant of 1.2M total shares (RSUs and PSUs).
- Enhanced severance package increases potential cash/equity liability in 'Change in Control' scenarios.
- Clawback-style provision: CEO must repay pre-tax value of RSUs if employment is terminated before August 16, 2025.
📋 Key Facts
- On June 23, 2025, the Company granted Amit Gupta 1,000,000 RSUs and 200,000 PSUs as part of an amended 'Second Tranche' equity award.
- The Second Tranche 2025 RSUs vest over two years (50% at one year, remainder quarterly).
- The Second Tranche 2025 PSUs are subject to a three-year performance period starting April 1, 2025, with no vesting before April 1, 2026.
- A potential additional grant of $5,000,000 in RSUs/PSUs is planned on or before May 31, 2026.
- Severance terms were amended to include 18 months of base salary and medical benefits if terminated without Cause or for Good Reason.
- Includes 'double-trigger' acceleration: unvested equity fully vests if terminated without Cause/Good Reason within three months before or one year after a Change in Control.
Cardlytics, Inc. held its 2025 Annual Meeting of Stockholders on May 20, 2025, where shareholders approved several key proposals including the election of three directors and a new equity incentive plan.
📋 Key Facts
- The 2025 Equity Incentive Plan was approved, authorizing up to 15,722,908 shares (comprising 10,000,000 new shares plus remaining/returned shares from previous plans).
- Three Class I directors—Jon Francis, Scott Hill, and Alex Mishurov—were elected to serve until the 2028 annual meeting.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2025.
- Shareholders approved executive compensation on a non-binding advisory basis (Say-on-Pay).
- The meeting saw a quorum of 65.31% of shares outstanding present or represented by proxy.
Cardlytics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal notification of the release of quarterly earnings and associated corporate highlights.
📋 Key Facts
- Reporting period: Three months ended March 31, 2025.
- Filing date: May 7, 2025.
- The company issued a press release (Exhibit 99.1) containing financial results and corporate highlights.
Cardlytics, Inc. announced that Bank of America has issued a non-renewal notice for its General Services Agreement, effective July 31, 2025. While an extension period is in place through January 27, 2026, the loss of this major partner represents a significant risk to the company's revenue stream.
🚩 Red Flags
- Loss of a major strategic partner (Bank of America) via non-renewal notice.
- Potential significant revenue impact following the expiration/extension period.
- Dependence on large financial institution partners for core business operations.
📋 Key Facts
- Bank of America issued a written non-renewal notice on April 22, 2025.
- The existing General Services Agreement (GSA) is set to expire on July 31, 2025.
- An extension period has been requested by Bank of America through January 27, 2026, to ensure uninterrupted operations.
- The company is currently in discussions with Bank of America regarding a potentially separate arrangement for digital channel offers.
- On April 16, 2025, the company amended its loan facility with Banc of California to extend the maturity date to April 15, 2028.
- The company maintains $60.0 million in unused available borrowings under the existing Loan Facility.
Cardlytics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024. The filing serves as a formal notice of the earnings release and accompanying press release.
📋 Key Facts
- Report date: March 12, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- The company issued a press release (Exhibit 99.1) containing financial results.
- A conference call was scheduled to discuss the results and recent corporate highlights.
Cardlytics, Inc. filed an 8-K to announce its financial results for the three and nine months ended September 30, 2024. The filing serves as a formal notice of the earnings release and accompanying conference call.
📋 Key Facts
- Reported date: November 6, 2024
- Period covered: Three and nine months ended September 30, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results and corporate highlights.
Cardlytics, Inc. announced the appointment of Srishti Gupta to its Board of Directors and the Nominating and Corporate Governance Committee on October 30, 2024.
📋 Key Facts
- Srishti Gupta appointed as a Class II director effective October 30, 2024.
- Gupta will serve on the Nominating & Corporate Governance (N&CG) Committee.
- Term expires at the Company's 2026 annual meeting of stockholders.
- Compensation includes 6,148 RSUs vesting on the first anniversary and an annual director retainer of $30,000 plus a $10,000 committee retainer.
- Gupta previously held senior leadership roles at Amazon (Director of Ads Measurement), Rokt (CPO), and Integral Ad Science (current CPO).
Cardlytics, Inc. entered into an amended and restated loan and security agreement with Banc of California, N.A. (formerly Pacific Western Bank) on September 30, 2024. The amendment serves to consolidate the original 2018 agreement and all subsequent amendments into a single document.
📋 Key Facts
- Date of Agreement: September 30, 2024
- Lender: Banc of California, N.A. (formerly Pacific Western Bank)
- Purpose: Amends and restates the original Loan and Security Agreement dated May 21, 2018.
- Nature of Change: Consolidation of the existing agreement and all subsequent amendments into one document; terms are consistent with previous filings except for immaterial changes.
Cardlytics, Inc. filed an amendment to its previous 8-K to detail the compensation package for newly appointed CEO Amit Gupta following the resignation of Karim Temsamani.
🚩 Red Flags
- CEO transition (leadership change) can introduce operational uncertainty, though no disagreement was noted.
- Significant potential equity dilution via upcoming RSU grants totaling up to $5M+ in value.
📋 Key Facts
- Karim Temsamani resigned as CEO and Board member effective August 16, 2024; resignation is not due to any disagreement with the company.
- Amit Gupta (formerly COO) appointed as CEO and Class II director effective August 16, 2024.
- Gupta's compensation includes a $550,000 annual base salary and a $275,000 one-time promotion bonus (subject to repayment if he leaves before Aug 2025).
- Gupta granted 500,000 RSUs vesting over 24 months in four installments.
- Potential for additional grants: 500,000 RSUs in January 2025 and a second tranche of up to $5,000,000 (max 1,000,000 shares) by May 31, 2025.
- Clawback provision: Gupta must repay the pre-tax value of vested RSUs if he terminates employment within 12 months of his start date.
Cardlytics, Inc. announced a leadership transition involving the resignation of CEO Karim Temsamani and the appointment of current COO Amit Gupta as his successor, effective August 16, 2024.
🚩 Red Flags
- Sudden leadership change (CEO departure) often introduces execution risk during transition periods.
- The exact terms of the new CEO's compensatory arrangement are not yet finalized or disclosed.
📋 Key Facts
- CEO Karim Temsamani is resigning from his roles as CEO and Board member, effective August 16, 2024.
- The company stated the resignation is not due to any disagreement regarding operations, policies, or practices.
- Amit Gupta, currently the Chief Operating Officer, has been appointed as the new CEO and principal executive officer.
- Amit Gupta will also join the Board of Directors as a Class II director with a term expiring at the 2026 Annual Meeting.
- The company expects to enter into amended compensatory arrangements for Mr. Gupta; details are pending.
- Financial results for the three and six months ended June 30, 2024, were released via press release.
Cardlytics, Inc. held its 2024 annual meeting of stockholders on May 23, 2024. The company successfully elected two Class III directors and ratified Deloitte & Touche LLP as its independent auditor.
🚩 Red Flags
- Significant 'Against' vote on Proposal 3 (Executive Compensation), though it was non-binding and passed.
📋 Key Facts
- Annual Meeting held on May 23, 2024.
- 74.12% of outstanding shares (35,710,280 out of 48,173,734) were present or represented by proxy.
- Andre Fernandez and Liane Hornsey were elected to the Board as Class III directors.
- Stockholders ratified Deloitte & Touche LLP as independent auditors for fiscal year ending Dec 31, 2024.
- Say-on-pay (Proposal 3) was approved on a non-binding advisory basis with 15,925,219 votes in favor.
Cardlytics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notification of the earnings release and associated press release.
📋 Key Facts
- Reported date: May 8, 2024
- Reporting period: Three months ended March 31, 2024
- The company issued a press release (Exhibit 99.1) containing financial results and corporate highlights.
- Information under Item 2.02 is furnished, not filed, meaning it is exempt from certain liabilities under Section 18 of the Exchange Act.
Cardlytics, Inc. announced the appointment of Liane Hornsey to its Board of Directors and as a member of the Compensation Committee. Ms. Hornsey is expected to assume the role of chairperson of the Compensation Committee following the company's 2024 annual meeting.
📋 Key Facts
- Liane Hornsey appointed as Class III director effective April 9, 2024.
- Ms. Hornsey will serve on the Compensation Committee and become its chair after the 2024 Annual Meeting.
- Compensation includes a grant of 1,326 restricted stock units (RSUs) vesting in one year.
- Annual director retainer is $30,000; Compensation Committee member retainer is $10,000 (increasing to $15,000 upon chair appointment).
- Ms. Hornsey has a background at Palo Alto Networks, Uber, SoftBank Group, and Google.
Cardlytics, Inc. completed a private offering of $172.5 million in 4.25% Convertible Senior Notes due 2029. The company utilized the proceeds and additional cash to repurchase approximately $183.9 million of its existing 1.00% Convertible Senior Notes due 2025.
🚩 Red Flags
- Potential dilution for existing shareholders via the issuance of up to 12.6 million new common shares upon conversion.
- Increased interest expense burden as the company shifts from 1.00% debt to 4.25% debt.
📋 Key Facts
- Completed offering of $172.5 million principal amount of 4.25% Convertible Senior Notes due 2029.
- Initial conversion price is approximately $18.02 per share (conversion rate: 55.4939 shares per $1,000).
- Notes carry a 4.25% annual interest rate, payable semi-annually on April 1 and October 1.
- Used ~$169.3 million to repurchase ~$183.9 million of existing 1.00% Convertible Senior Notes due 2025.
- Maximum shares issuable upon conversion: 12,683,821 shares.
Cardlytics, Inc. completed an 'at the market' (ATM) equity offering program on March 18, 2024. The company sold 3,907,600 shares of common stock to raise $50 million in gross proceeds.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of 3.9 million new shares.
📋 Key Facts
- Completed ATM Offering Program on March 18, 2024.
- Total aggregate gross proceeds: $50.0 million.
- Shares sold: 3,907,600 shares of common stock.
- Weighted average price per share: $12.80.
- Sales agents included Evercore Group L.L.C., BofA Securities, Inc., and Cantor Fitzgerald & Co.
Cardlytics, Inc. entered into an Equity Distribution Agreement to establish an 'at-the-market' (ATM) offering of up to $50.0 million in common stock.
🚩 Red Flags
- Potential for immediate share dilution as the company may issue and sell common stock into the market via the ATM program.
📋 Key Facts
- Entered into an Equity Distribution Agreement on March 18, 2024.
- Sales Agents: Evercore Group L.L.C., BofA Securities, Inc., and Cantor Fitzgerald & Co.
- Maximum aggregate offering amount: $50.0 million in common stock (ATM Shares).
- Commission rate to Sales Agents: up to 3.0% of gross proceeds.
- The company is not obligated to sell any shares under this agreement.
Cardlytics, Inc. entered into a material agreement with American Express Travel Related Services Company, Inc. to provide its proprietary marketing platform for card-linked offers. The agreement features an initial three-year term and includes a reimbursement obligation by Cardlytics for cash-back rewards distributed to American Express cardmembers.
🚩 Red Flags
- Termination for convenience clause allows American Express to exit the agreement with 90 days' notice, reducing long-term revenue certainty.
📋 Key Facts
- Agreement entered into on March 14, 2024, with American Express Travel Related Services Company, Inc. (AXP).
- The agreement provides AXP access to Cardlytics' proprietary marketing platform for card-linked offers.
- Initial term begins when the Platform is first made available to Cardmembers and lasts for three years.
- AXP maintains a termination right for convenience upon 90 days' written notice for the majority of the Term.
- Cardlytics is responsible for reimbursing AXP for cash-back rewards distributed to Cardmembers.
Cardlytics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023. The filing includes a press release and an earnings presentation as exhibits.
📋 Key Facts
- Reported date: March 14, 2024
- Period covered: Quarter and Year ended December 31, 2023
- Includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Earnings Presentation)
- Signed by Alexis DeSieno, Chief Financial Officer
Cardlytics, Inc. entered into a settlement agreement with Shareholder Representative Services LLC (SRS) to resolve all disputes arising from the 2021 Merger Agreement and related earnout payments. The settlement involves significant cash outflows and equity issuance.
🚩 Red Flags
- Significant immediate cash outflow: $20.0 million due by January 30, 2024 (within days of filing).
- Equity dilution: Issuance of 3.6 million new shares of common stock.
- Resolution of litigation involving earnout disputes from a prior merger suggests significant historical liability/disagreement.
📋 Key Facts
- Settlement amount includes $25.0 million in total cash payments and 3.6 million shares of common stock.
- Cash payment schedule: $20.0M by Jan 30, 2024; $3.0M by Jan 31, 2025; $2.0M by June 30, 2025.
- Equity issuance of 3.6 million shares to be completed by February 4, 2024.
- The agreement resolves disputes regarding 'First Anniversary' and 'Second Anniversary' payment amounts from the April 12, 2021 Merger Agreement.
- Company must dismiss its lawsuit against SRS in the Delaware Court of Chancery with prejudice.
Cardlytics, Inc. announced a significant board reshuffle effective January 1, 2024, involving the appointment of two new directors and the resignation of two long-standing board members. The changes include the appointment of Andre Fernandez to the Audit Committee and Jack Klinck as Board Chairperson.
🚩 Red Flags
- Departure of two long-tenured board members (Balen since 2008, Adams since 2011) in a single filing.
- Multiple changes to committee leadership and board composition occurring simultaneously.
📋 Key Facts
- Effective Jan 1, 2024: Andre Fernandez appointed as Director and Audit Committee member; previously CFO at WeWork and EVP/CFO at NCR.
- Effective Jan 1, 2024: Jon Francis appointed as Director; currently Chief Data and Analytics Officer at General Motors.
- Effective Jan 1, 2024: John V. Balen resigned as Chairperson of the Board and from Nominating/Governance and Compensation committees (served since 2008).
- Effective Jan 1, 2024: David Adams resigned from the Board and as Audit Committee Chair.
- Jack Klinck appointed as Chairperson of the Board and Chairperson of the Nominating and Corporate Governance Committee.
- Scott Hill appointed as Chairperson of the Audit Committee.